'''Canrenone''' (brand names '''Contaren''', '''Luvion''', '''Phanurane''', '''Spiroletan''') is a [[steroid]]al [[antimineralocorticoid]]<ref name="pmid4039568">{{cite journal |last1=Losert |first1=W |last2=Casals-Stenzel |first2=J |last3=Buse |first3=M |title=Progestogens with antimineralocorticoid activity |journal=Arzneimittelforschung |volume=35 |issue=2 |pages=459–71 |year=1985 |pmid=4039568 |doi= |url=}}</ref><ref name="pmid6849751">{{cite journal |last1=Fernandez |first1=MD |last2=Carter |first2=GD |last3=Palmer |first3=TN |title=The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol |journal=Br J Clin Pharmacol |volume=15 |issue=1 |pages=95–101 |year=1983 |pmid=6849751 |pmc=1427833 |doi= 10.1111/j.1365-2125.1983.tb01470.x|url=}}</ref> of the [[spirolactone]] group related to [[spironolactone]] which is used as a [[diuretic]] in [[Europe]], including in [[Italy]] and [[Belgium]].<ref name="HillMakin1991">{{cite book |first1=R.A. |last1=Hill |first2=H.L.J. |last2=Makin |first3=D.N. |last3=Kirk |first4=G.M. |last4=Murphy |title=Dictionary of Steroids |url=https://books.google.com/books?id=qw5X0NK1A90C&pg=PA656 |date=23 May 1991 |publisher=CRC Press |isbn=978-0-412-27060-4 |pages=656–}}</ref><ref name="pmid15082604">{{cite journal |last1=Romanelli |first1=RG |last2=Gentilini |first2=P |title=Cross reactivity due to positive canrenone interference |journal=Gut |volume=53 |issue=5 |pages=772–3 |date=May 2004 |pmid=15082604 |pmc=1774040 |doi= |url=http://gut.bmj.com/cgi/pmidlookup?view=long&pmid=15082604}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA167|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=167–}}</ref> It is also an important [[active metabolite]] of spironolactone, and partially accounts for its therapeutic effects.<ref name="ClarkHarvey2011" /><ref name="pmid2723123" />

 
Canrenone is an [[active metabolite|active]] [[metabolite]] of spironolactone, [[canrenoic acid]], and [[potassium canrenoate]], and is considered to be partially responsible for their effects.<ref name="ClarkHarvey2011">{{cite book |first1=Michelle A. |last1=Clark |first2=Richard A. |last2=Harvey |first3=Richard |last3=Finkel |first4=Jose A. |last4=Rey |first5=Karen |last5=Whalen |title=Pharmacology |url=https://books.google.com/books?id=Y558dgp_PjoC&pg=PA286 |date=15 December 2011 |publisher=Lippincott Williams & Wilkins |isbn=978-1-4511-1314-3 |pages=286–}}</ref> It has been found to account for approximately 10 to 25% of the [[potassium-sparing diuretic|potassium-sparing effect]] of spironolactone,<ref name="GinésArroyo2008">{{cite book|author1=Pere Ginés|author2=Vicente Arroyo|author3=Juan Rodés |author4=Robert W. Schrier |title=Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment|url=https://books.google.com/books?id=Z3PARx4oYDgC&pg=PR6|date=15 April 2008|publisher=John Wiley & Sons|isbn=978-1-4051-4370-7|page=[https://www.researchgate.net/profile/Carlos_Terra/publication/227982015_Hepatorenal_Syndrome_in_Cirrhosis_Clinical_Features_Diagnosis_and_Management/links/54479d460cf2d62c30508b3b.pdf#page=234 229]}}</ref> whereas another metabolite, [[7α-thiomethylspironolactone]] (7α-TMS), accounts for around 80% of the potassium-sparing effect of the drug.<ref name="pmid18729003">{{cite journal | vauthors = Maron BA, Leopold JA | title = Mineralocorticoid receptor antagonists and endothelial function | journal = Curr Opin Investig Drugs | volume = 9 | issue = 9 | pages = 963–9 | year = 2008 | pmid = 18729003 | pmc = 2967484 | doi = | url = }}</ref><ref name="CancerOrganization2001">{{cite book|author1=International Agency for Research on Cancer|author2=World Health Organization|title=Some Thyrotropic Agents|url=https://books.google.com/books?id=l965aqw_LSkC&pg=PA325|year=2001|publisher=World Health Organization|isbn=978-92-832-1279-9|pages=325–}}</ref><ref name="pmid23063964">{{cite journal | vauthors = Agusti G, Bourgeois S, Cartiser N, Fessi H, Le Borgne M, Lomberget T | title = A safe and practical method for the preparation of 7α-thioether and thioester derivatives of spironolactone | journal = Steroids | volume = 78 | issue = 1 | pages = 102–7 | year = 2013 | pmid = 23063964 | doi = 10.1016/j.steroids.2012.09.005 | url = }}</ref>
